Structural conservation of druggable Hot spots in protein - Protein interfaces

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 33, 2011, Pages 13528-13533

  Kozakov, Dima ^a   Hall, David R ^a   Chuang, Gwo Yu ^a   Cencic, Regina ^c,d   Brenke, Ryan ^a   Grove, Laurie E ^e   Beglov, Dmitri ^a   Pelletier, Jerry ^c,d   Whitty, Adrian ^b   Vajda, Sandor ^a,b  

^a Boston University   (United States)

^b Boston University   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e WENTWORTH INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Fragment based drug discovery; Inhibitor design; Ligand binding site; Side chain adjustment

Indexed keywords

HPV TRANSCRIPTION FACTOR E2; INITIATION FACTOR 4E; INITIATION FACTOR 4G; NUCLEAR PROTEIN; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN ZIPA; TRANSCRIPTION FACTOR E2A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; BINDING SITE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE;

EID: 80051966197     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1101835108     Document Type: Article

References (46)

1. Wells J., McClendon C. (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450:1001-1009. (Pubitemid 350273630)
2. Whitty A., Kumaravel G. (2006) Between a rock and a hard place? Nat Chem Biol 2:112-118. (Pubitemid 44323856)
3. Berg T. (2008) Small-molecule inhibitors of protein-protein interactions. Curr Opin Drug Discov Devel 11:666-674.
4. Fuller J.C., Burgoyne N.J., Jackson R.M. (2009) Predicting druggable binding sites at the protein-protein interface. Drug Disc Today 14:155-161.
5. Laskowski R.A., Luscombe N.M., Swindells M.B., Thornton J.M. (1996) Protein clefts in molecular recognition and function. Protein Sci 5:2438-2452. (Pubitemid 26424856)
6. An J., Totrov M., Abagyan R. (2005) Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol Cell Proteomics 4:752-761. (Pubitemid 40873004)
7. Nayal M., Honig B. (2006) On the nature of cavities on protein surfaces: Application to the identification of drug-binding sites. Proteins 63:892-906. (Pubitemid 43765141)
8. Brown S.P., Hajduk P.J. (2006) Effects of conformational dynamics on predicted protein druggability. ChemMedChem 1:70-72. (Pubitemid 44104979)
9. Eyrisch S., Helms V. (2007) Transient pockets on protein surfaces involved in proteinprotein interaction. J Med Chem 50:3457-3464. (Pubitemid 47195455)
10. Clackson T., Wells J.A. (1995) A hot spot of binding energy in a hormone-receptor interface. Science 267:383-386.
11. Hajduk P.J., Huth J.R., Fesik S.W. (2005) Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 48:2518-2525. (Pubitemid 40516441)
12. Mattos C., Ringe D. (1996) Locating and characterizing binding sites on proteins. Nat Biotechnol 14:595-599. (Pubitemid 26135122)
13. Dennis S., Kortvelyesi T., Vajda S. (2002) Computational mapping identifies the binding sites of organic solvents on proteins. Proc Natl Acad Sci USA 99:4290-4295. (Pubitemid 34285978)
14. Landon M.R., Lancia D.R., Jr, Yu J., Thiel S.C., Vajda S. (2007) Identification of hot spots within druggable binding sites of proteins by computational solvent mapping. J Med Chem 50:1231-1240. (Pubitemid 46496323)
15. Brenke R., et al. (2009) Fragment-based identification of druggable "hot spots" of proteins using Fourier domain correlation techniques. Bioinformatics 25:621-627.
16. Goodford P.J. (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28:849-875.
17. Miranker A., Karplus M. (1991) Functionality maps of binding sites: A multiple Copy simultaneous search method. Proteins 11:29-34.
18. Landon M.R., et al. (2008) Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble. Chem Biol Drug Des 71:106-116. (Pubitemid 351160979)
19. Christ F., et al. (2010) Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 6:442-448.
20. Silvian L.F., et al. (2011) Small molecule inhibition of the TNF family cytokine CD40 ligand through a subunit fracture mechanism. ACS Chem Biol 6:636-647.
21. Cachero T.G., et al. (2006) Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor). Biochemistry 45:2006-2013. (Pubitemid 43271300)
22. Graff J.R., Konicek B.W., Carter J.H., Marcusson E.G. (2008) Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68:631-634. (Pubitemid 351206735)
23. Moerke N.J., et al. (2007) Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128:257-267. (Pubitemid 46137991)
24. Cencic R., et al. (2011) Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci USA 108:1046-1051.
25. Rickert M., Wang X., Boulanger M.J., Goriatcheva N., Garcia K.C. (2005) The structure of interleukin-2 complexed with its alpha receptor. Science 308:1477-1480. (Pubitemid 40791303)
26. Tilley J.W., et al. (1997) Identification of a small molecule inhibitor of the IL-2/IL-2R alpha receptor interaction which binds to IL-2. J Am Chem Soc 119:7589-7590. (Pubitemid 27355129)
27. Arkin M., et al. (2003) Binding of small molecules to an adaptive protein-protein interface. Proc Natl Acad Sci USA 100:1603-1608. (Pubitemid 36254494)
28. Braisted A., et al. (2003) Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J Am Chem Soc 125:3714-3715. (Pubitemid 36512355)
29. Sattler M., et al. (1997) Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science 275:983-986. (Pubitemid 27087715)
30. Oltersdorf T., et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681. (Pubitemid 40825512)
31. Lee E.F., et al. (2007) Crystal structure of ABT-737 complexed with Bcl-xL: Implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14(9):1711-1713. (Pubitemid 47278856)
32. Momand J., Wu H., Dasgupta G. (2000) MDM2-master regulator of the p53 tumor suppressor protein. Gene 242:15-29. (Pubitemid 30064488)
33. Kussie P.H., et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274(5289):948-53. (Pubitemid 26398409)
34. Vassilev L., et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848. (Pubitemid 38174664)
35. Abbate E.A., Berger J.M., Botchan M.R. (2004) The X-ray structure of the papillomavirus helicase in complex with its molecular matchmaker E2. Genes Dev 18:1981-1996. (Pubitemid 39071580)
36. Wang Y., et al. (2004) Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor. J Biol Chem 279:6976-6985. (Pubitemid 38248841)
37. Mosyak L., et al. (2000) The bacterial cell-division protein ZipA and its interaction with an FtsZ fragment revealed by X-ray crystallography. EMBO J 19:3179-3191. (Pubitemid 30428197)
38. Jennings L.D., et al. (2004) Design and synthesis of indolo[2,3-a] quinolizin-7-one inhibitors of the ZipA-FtsZ interaction. Bioorg Med Chem Lett 14:1427-1431. (Pubitemid 38299423)
39. Tsao D.H., et al. (2006) Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. Bioorg Med Chem 14:7953-7961. (Pubitemid 44584704)
40. Rush T.S., 3rd, Grant J.A., Mosyak L., Nicholls A. (2005) A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J Med Chem 48:1489-1495. (Pubitemid 40364556)
41. He M.M., et al. (2005) Small-molecule inhibition of TNF-alpha. Science 310:1022-1025.
42. Li X., Keskin O., Ma B., Nussinov R., Liang J. (2004) Protein-protein interactions: Hot spots and structurally conserved residues often locate in completed pockets that preorganized in the unbound states: Hot spots and structurally conserved residues often locate in completed pockets that preorganized in the unbound statesImplications for docking. J Mol Biol 344:781-785.
43. Berman H., et al. (2000) The Protein Data Bank. Nucl Acids Res 28:235-242. (Pubitemid 30047768)
44. Dunbrack R.L., Karplus M. (1993) Backbone-dependent rotamer library for proteins. Application to side-chain prediction. J Mol Biol 230:543-574.
45. Verdonk M.L., Mortenson P.N., Hall R.J., Hartshorn M.J., Murray C.W. (2008) Protein-ligand docking against non-native protein conformers. J Chem Inf Model 48:2214-2225.
46. Trott O., Olson A.J. (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455-461.